AXQ Capital LP Invests $897,000 in Corteva, Inc. $CTVA

AXQ Capital LP purchased a new stake in shares of Corteva, Inc. (NYSE:CTVA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,262 shares of the company’s stock, valued at approximately $897,000.

A number of other hedge funds also recently added to or reduced their stakes in CTVA. Compound Planning Inc. increased its position in Corteva by 14.5% during the 3rd quarter. Compound Planning Inc. now owns 10,288 shares of the company’s stock valued at $696,000 after purchasing an additional 1,301 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Corteva by 30.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,347 shares of the company’s stock valued at $226,000 after purchasing an additional 788 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its stake in shares of Corteva by 4.2% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 4,808 shares of the company’s stock valued at $325,000 after purchasing an additional 196 shares in the last quarter. Legacy Financial Advisors Inc. increased its holdings in Corteva by 3.2% during the third quarter. Legacy Financial Advisors Inc. now owns 10,312 shares of the company’s stock valued at $697,000 after buying an additional 324 shares during the period. Finally, Clearstead Advisors LLC raised its stake in Corteva by 9.0% in the third quarter. Clearstead Advisors LLC now owns 13,349 shares of the company’s stock worth $903,000 after buying an additional 1,104 shares in the last quarter. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Trading Up 0.1%

NYSE CTVA opened at $76.42 on Tuesday. Corteva, Inc. has a 12-month low of $53.40 and a 12-month high of $77.41. The company has a fifty day simple moving average of $70.93 and a two-hundred day simple moving average of $68.60. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. The stock has a market cap of $51.39 billion, a P/E ratio of 48.37, a P/E/G ratio of 2.60 and a beta of 0.75.

Corteva (NYSE:CTVA) last released its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.During the same period in the prior year, the firm earned $0.32 EPS. The firm’s revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts forecast that Corteva, Inc. will post 2.96 earnings per share for the current year.

Corteva Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Monday, March 2nd. Corteva’s dividend payout ratio (DPR) is presently 45.57%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CTVA. Mizuho increased their target price on Corteva from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, February 17th. Wells Fargo & Company upped their price objective on Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Royal Bank Of Canada raised their price objective on Corteva from $80.00 to $89.00 and gave the company an “outperform” rating in a research report on Thursday, February 5th. CICC Research lifted their target price on Corteva from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Finally, JPMorgan Chase & Co. lowered shares of Corteva from an “overweight” rating to a “neutral” rating and increased their price target for the company from $75.00 to $77.00 in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $82.30.

Corteva Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.